Literature DB >> 12742136

Analysis of diclofenac and its metabolites by high-performance liquid chromatography: relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios.

Pedro Dorado1, Roland Berecz, Macarena C Cáceres, Adrián LLerena.   

Abstract

In humans, diclofenac is metabolised to 4'-hydroxy (OH), 3'-OH and 5-OH metabolites. The polymorphic CYP2C9 is involved in the metabolism of diclofenac to 4'-OH diclofenac and 3'-OH diclofenac. The aim of the present study was to develop a high-performance liquid chromatographic method to simultaneously measure diclofenac and its metabolites in urine, suitable for metabolic studies. After liquid-liquid extraction the compounds were separated in a reversed-phase column and measured by ultraviolet absorption at 282 nm. For all compounds intra-day and inter-day variations were less than 7%, and the limits of quantitation were 0.25 mg/l. No analytical interference with endogenous compounds was found. The relationship between diclofenac metabolic ratios among different CYP2C9 genotypes is reported. The CYP2C9*3/*3 subject had the highest diclofenac/4'-OH ratios. However no difference was found between CYP2C9*2/*2 and *1/*1 genotypes. The chromatographic method developed was sensitive and reliable for the measurement of diclofenac and its metabolites simultaneously in human urine, and is suitable for use in diclofenac metabolism studies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12742136     DOI: 10.1016/s1570-0232(03)00137-5

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers.

Authors:  P Dorado; I Cavaco; M C Cáceres; R Piedade; V Ribeiro; A Llerena
Journal:  Eur J Clin Pharmacol       Date:  2008-06-12       Impact factor: 2.953

2.  Reproducibility over time of the urinary diclofenac/4'-OH diclofenac ratio among different CYP2C9 genotypes.

Authors:  Pedro Dorado; Roland Berecz; Macarena C Cáceres; Idilio Conzález; Adrián Llerena
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2003 Jul-Sep       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.